ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Counterfactual Impact of the Pneumococcal Vaccine Advanced Market Commitment
2
3
ItemValueSource
4
Proportion of PCV coverage across GAVI countries across 12 years from introduction, with AMC: Calculated by taking a population-weighted average of coverage rates per country-year across all 54 current GAVI countries across 12 years (from introduction in 2010 up to 2021)
0.49See PCV Coverage sheet
5
Proportion of RV coverage across GAVI countries across first 12 years: Calculated by taking a population-weighted average of coverage rates per country-year across all 54 current GAVI countries across 12 years (from introduction in 2006 up to 2017, for comparability).
0.12See RV Coverage sheet
6
Proportion of HPV coverage across GAVI countries across first 12 years: Calculated by taking a population-weighted average of coverage rates per country-year across all 54 current GAVI countries across 12 years (from introduction in 2010 up to 2021).
0.02See HPV Coverage sheet
7
Proportion of YF coverage across GAVI countries across first 12 years: Calculated by taking a population-weighted average of coverage rates per country-year across all 54 current GAVI countries across 12 years (from GAVI making a concerted effort on YF in 2001 up to 2012, for comparability)
0.09See YFV Coverage sheet
8
Proportion of PCV coverage across GAVI countries across 12 years from introduction, without AMC: Weighted average that (a) penalizes dissimilarity in target demographics (n.b. PCV and RV are both targeted for <1 year olds, while HPV is for older individuals even as is the YF vaccine for 9 months+ individuals), which matters insofar as the former two vaccines will more likely be deployed as part of post-birth immunization schedule; and (b) penalizes data limitations (e.g. the uncertain YF extrapolations).
0.11
9
Counterfactual impact of the PCV AMC as a proportion of total disease burden avertable by vaccinations in relevant time period (Best estimate)
0.38
10
Counterfactual impact of the PCV AMC as a proportion of total disease burden avertable by vaccinations in relevant time period (Single RV reference class estimate)
0.37
11
Difference2%
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100